[HTML][HTML] Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
Q He, J Liu, X Cai, M He, C Li, H Liang… - Translational Lung …, 2021 - ncbi.nlm.nih.gov
Background Several randomized controlled trials have suggested that adjuvant epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) were associated with
prolonged disease-free survival (DFS) in EGFR-mutated NSCLC patients after radical
resection, comparing with chemotherapy or placebo. We aimed to compare the effectiveness
of different first-generation EGFR-TKIs as adjuvant treatment in real-world setting. Methods
Early-stage EGFR mutated NSCLC patients who underwent radical resection and treated …
growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) were associated with
prolonged disease-free survival (DFS) in EGFR-mutated NSCLC patients after radical
resection, comparing with chemotherapy or placebo. We aimed to compare the effectiveness
of different first-generation EGFR-TKIs as adjuvant treatment in real-world setting. Methods
Early-stage EGFR mutated NSCLC patients who underwent radical resection and treated …
68P Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
W Liang, Q He, C Li, H Liang, B Cheng, J He - Journal of Thoracic Oncology, 2021 - jto.org
Background: Several randomized controlled trials have suggested that adjuvant epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) were associated with
prolonged disease-free survival (DFS) in EGFR-mutated NSCLC patients after radical
resection, comparing with chemotherapy or placebo. Herein, we aimed to compare the
effectiveness of different first-generation EGFR-TKIs as adjuvant treatment in real-world
setting. Methods: Early stage EGFR mutated NSCLC patients who underwent radical …
growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) were associated with
prolonged disease-free survival (DFS) in EGFR-mutated NSCLC patients after radical
resection, comparing with chemotherapy or placebo. Herein, we aimed to compare the
effectiveness of different first-generation EGFR-TKIs as adjuvant treatment in real-world
setting. Methods: Early stage EGFR mutated NSCLC patients who underwent radical …
以上显示的是最相近的搜索结果。 查看全部搜索结果